Illumina, Inc. (NASDAQ:ILMN)’s share price hit a new 52-week high on Wednesday following a stronger than expected earnings report. The stock traded as high as $196.72 and last traded at $196.79, with a volume of 3,460,068 shares. The stock had previously closed at $172.30.

The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. The firm had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $0.86 EPS.

ILMN has been the topic of a number of research reports. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective on the stock. in a report on Wednesday, May 31st. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $195.00 target price on the stock in a report on Thursday, July 27th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and raised their target price for the company from $170.00 to $215.00 in a report on Monday, August 7th. First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price on the stock in a report on Wednesday, August 2nd. Finally, Barclays PLC reiterated an “equal weight” rating and set a $150.00 target price on shares of Illumina in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $177.01.

In other Illumina news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction on Monday, June 5th. The stock was sold at an average price of $184.75, for a total transaction of $26,788.75. Following the sale, the senior vice president now owns 10,791 shares of the company’s stock, valued at approximately $1,993,637.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Omead Ostadan sold 1,671 shares of Illumina stock in a transaction on Monday, August 7th. The shares were sold at an average price of $195.26, for a total value of $326,279.46. Following the sale, the executive vice president now directly owns 24,571 shares in the company, valued at approximately $4,797,733.46. The disclosure for this sale can be found here. Insiders have sold a total of 134,010 shares of company stock valued at $23,946,015 in the last 90 days. Insiders own 1.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in ILMN. Nisa Investment Advisors LLC increased its stake in shares of Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock valued at $1,056,000 after buying an additional 1,800 shares during the last quarter. State of Tennessee Treasury Department increased its stake in shares of Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock valued at $16,697,000 after buying an additional 7,040 shares during the last quarter. Bank of Nova Scotia increased its stake in shares of Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock valued at $14,710,000 after buying an additional 62,612 shares during the last quarter. Aberdeen Asset Management PLC UK increased its stake in shares of Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock valued at $4,775,000 after buying an additional 2,158 shares during the last quarter. Finally, Eastern Bank acquired a new stake in shares of Illumina during the first quarter valued at $256,000. 93.81% of the stock is currently owned by hedge funds and other institutional investors.

The company has a 50 day moving average price of $179.63 and a 200-day moving average price of $173.73. The stock has a market cap of $28.36 billion, a P/E ratio of 38.97 and a beta of 0.83.

WARNING: This report was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2017/08/12/illumina-inc-ilmn-sets-new-12-month-high-on-better-than-expected-earnings-updated.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.